Oncotarget

Research Papers:

Neutrophil-to-lymphocyte ratio as a predictive or prognostic factor for gastric cancer treated with nivolumab: a multicenter retrospective study

Takatsugu Ogata, Hironaga Satake _, Misato Ogata, Yukimasa Hatachi, Kentaro Inoue, Madoka Hamada and Hisateru Yasui

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2018; 9:34520-34527. https://doi.org/10.18632/oncotarget.26145

Metrics: PDF 940 views  |   HTML 1306 views  |   ?  


Abstract

Takatsugu Ogata1, Hironaga Satake2, Misato Ogata1, Yukimasa Hatachi1, Kentaro Inoue3, Madoka Hamada3 and Hisateru Yasui1

1Department of Medical Oncology, Kobe City Medical Center General Hospital, Chuo-ku, Kobe City, Hyogo, 650-0047, Japan

2Cancer Treatment Center, Kansai Medical University Hospital, Shinmachi, Hirakata City, Osaka, 573-1191, Japan

3Department of Surgery, Kansai Medical University Hospital, Shinmachi, Hirakata City, Osaka, 573-1191, Japan

Correspondence to:

Hironaga Satake, email: takeh1977@gmail.com

Keywords: advanced gastric cancer; nivolumab; neutrophil-to-lymphocyte ratio; predictive factors; prognostic factors

Received: May 28, 2018    Accepted: September 08, 2018    Published: October 02, 2018

ABSTRACT

Introduction: The neutrophil-to-lymphocyte ratio (NLR) is effective as a predictive factor for lung cancer treated with nivolumab. The objective of this study was to determine the effectiveness of NLR for patients with advanced gastric cancer (AGC) treated with nivolumab.

Methods: This was a multicenter, retrospective study of patients with AGC treated with nivolumab from June 2017 to December 2017. The NLRs were calculated before the first cycle (NLRpre) and two weeks after the first administration (NLRpost).

Results: Twenty-six patients were enrolled (males 19, females 7) with a median age of 64 years. The overall response rate was 15%. The median PFS was 80 days (range, 11 – 265) and the median OS was 290 days (range, 21 – 332). Stratified with high NLR (≥5) and low NLR (<5), the median PFS was shorter in the high NLRpre arm (87 vs. 45 days; p=0.066) and significantly shorter in the high NLRpost arm (94 vs. 28 days; p=0.014). The median OS was significantly shorter in the high NLRpre arm (290 vs. 175 days; p=0.008) and in the high NLRpost arm (290 vs. 69 days; p<0.001).

Conclusion: NLR may be an effective prognostic factor in patients with AGC treated with nivolumab.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 26145